2015 Consensus terminology and classification of persistent vulvar pain

Dear ISSWSH Members

Since the previous terminology of vulvodynia was accepted by the International Society for the Study of Vulvovaginal Disorders (ISSVD) in 2003, studies have explored possible causative factors and treatment options. The International Society for the Study of Women's Sexual Health (ISSWSH), The International Society for the Study of Vulvovaginal Disorders (ISSVD) and the International Pelvic Pain Society (IPPS) believed there was an unmet medical need for a comprehensive, evidence-based set of vulvovaginal pain diagnoses that can be easily utilized by both expert and non-expert healthcare providers to establish diagnoses in their patients and to guide treatment. Therefore we discussed the possibility of revision of 2003 terminology and organized an ISSWSH sponsored international meeting in order to reach a consensus on the terminology of vulvar pain, April 8 - 9, 2015 in Annapolis, Maryland. The American College of Obstetricians and Gynecologists (ACOG) and the National Vulvodynia Association (NVA) were also represented.

Read more: 2015 Consensus terminology and classification of...


Flibanserin approved as the FIRST pharmacologic treatment option for women suffering from hypoactive sexual desire disorder

Dear ISSWSH members,

It is with tremendous excitement that we share the announcement that flibanserin, a drug for acquired, generalized hypoactive sexual desire disorder (HSDD) developed by Sprout Pharmaceuticals, was approved by the FDA on August 18, 2015. This follows the June 4, 2015 meeting of their Advisory Committee whose members voted 18-6 for approval.

Read more: Flibanserin approved as the FIRST pharmacologic...


General Statement of the International Society for the Study of Women's Sexual Health

The International Society for the Study of Women's Sexual Health (ISSWSH), the preeminent scientific organization focused on research, education, and clinical practice of women's sexuality, applauds the FDA's recent announcement of it's upcoming Joint Meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee on June 4, 2015.

Read more: General Statement of the International Society...


FDA announced a Public Advisory Committee Meeting

FDA announced a Public Advisory Committee Meeting to review the approval of flibanserin for hypoactive sexual desire disorder (HSDD) in women on June 4, 2015. Should you wish to submit your written comments or request time at the public microphone, the deadline is a week away. Please find all details in the Federal Register Notice by clicking on this link. - -


Information about the ISSWSH Business Meeting

The ISSWSH Business Meeting will take place in the Capitol Ballroom A-D of the Sheraton Austin Hotel at the Capitol in Austin, TX on Friday February 20, 2015. The meeting is scheduled for 60 minutes from 5:00 - 6:00 pm.

Save the Date

ISSWSH Fall Course 2020
Cancelled

ISSWSH Virtual Course 2020
November 6, 13, & 20, 2020  
Virtual
Stay tuned for updates

ISSWSH Annual Meeting 2021
March 4-7, 2021   164 days left
Renaissance Dallas Hotel, Dallas, TX, USA

Latest Tweets

@ISSM_INFO is seeking committee members for the International Consultation on Sexual Medicine for Female Sexual Pai… https://t.co/sSLQV9dG5Z ISSWSH
Menopause apps are taking cues from the period tracking apps and have recently gained popularity. How can these ap… https://t.co/fjUybFZtxp ISSWSH
Apply for ISSWSH membership today and receive membership until the end of 2021 for only one annual fee! This offer… https://t.co/lnuft3wNlx ISSWSH

Contact Details

ISSWSH Executive Office
14305 Southcross Dr
Suite 100
Burnsville, MN 55306
USA

Phone: +1 (952) 683 9025
Fax: +1 (952) 314 8212
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Follow Us

On Twitter
On Facebook
On Instagram